EGFR and non-small cell lung carcinoma: PAPILLON trial is a phase 3, international, randomized trial designed to evaluate the efficacy and safety of amivantamab plus carboplatin–pemetrexed (amivantamab–chemotherapy) against standard chemotherapy as a first-line regimen for patients diagnosed with advanced NSCLC harboring EGFR exon 20 insertion mutations.